Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 3/2015

01-03-2015 | Erratum

Erratum to: Does saturable formation of gemcitabine triphosphate occur in patients?

Authors: Lai-San Tham, Ling-Zhi Wang, Ross A. Soo, How-Sung Lee, Soo-Chin Lee, Boon-Cher Goh, Nicholas H. G. Holford

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2015

Login to get access

Excerpt

The author would like to correct the errors in the publication of the original article. The corrected details are given below for your reading. …
Metadata
Title
Erratum to: Does saturable formation of gemcitabine triphosphate occur in patients?
Authors
Lai-San Tham
Ling-Zhi Wang
Ross A. Soo
How-Sung Lee
Soo-Chin Lee
Boon-Cher Goh
Nicholas H. G. Holford
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 3/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-015-2678-y

Other articles of this Issue 3/2015

Cancer Chemotherapy and Pharmacology 3/2015 Go to the issue

Original Article

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Original Article

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine

Original Article

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Original Article

The newly synthesized anticancer drug HUHS1015 is useful for treatment of human gastric cancer

Original Article

A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer

Original Article

Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits